Axsome Therapeutics

CNS Pipeline Advancements Will Expand Global Reach

AnalystConsensusTarget

Not Invested

Based on Analyst Price Targets

Published

28 Apr 25

Updated

07 Nov 25

n/a

AnalystConsensusTarget's Fair Value

n/a

49.1%

-1.5%

49.1%

-1.5%

You can edit this narrative until Nov 8 7:10 AM. Then, changes will post as Updates.

Author's Valuation

US$181.5817.8% undervalued

AnalystConsensusTarget Fair Value

Narrative

Updates2

Shared on 07 Nov 25

Fair value Increased 2.68%

AXSM: Commercial Execution And Late-Stage Pipeline Will Drive Strong Upside Potential

Axsome Therapeutics' fair value estimate has been raised by analysts from $176.84 to $181.58. This change reflects upward price target revisions, as analysts express optimism about the company's progress toward profitability and effective commercial execution following recent quarterly results.

Shared on 01 May 25

Fair value Increased 0.03%

AnalystConsensusTarget Fair Value

US$181.58

17.8% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

34.52%

Pharma revenue growth rate

0.68%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

6.96%

Calculation

US$531.66m

Earnings '28

23.40x

PE Ratio '28

US$12.44b

Market Cap '28

US$12.44b

Market Cap '28

56.75m

No. shares '28

US$219.24

Share Price '28

US$219.24 Share Price '28

Discounted to 2025 @ 6.96% p.a.

US$179.19

Fair Value '25